Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 25;11(10):471-473.
doi: 10.1093/jpids/piac076.

Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain

Cristina Epalza  1   2   3   4 , Luis Prieto-Tato  1   2   3   4 , Rosa Pino  5 , Paula Escartín-Paredes  1 , Inés Leoz  6 , Carlos Grasa  7   8 , Ana Vivanco-Allende  9 , Jacques G Rivière  10   11   12 , Jaume Carrasco-Colom  13 , Olatz Villate  14 , Victoria Fumadó  15 , Concepción Hermoso-Ibañez  1 , Blanca Herrero  16 , David Aguilera-Alonso  2   3   4   17   18 , Alfredo Tagarro  2   3   4   19 , Cinta Moraleda  1   2   3   4 ; EPICO-AEP Working Group
Affiliations

Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain

Cristina Epalza et al. J Pediatric Infect Dis Soc. .

Abstract

In this cohort of 42 adolescents with a previous multisystem inflammatory syndrome (MIS-C) diagnosis, 32 (76.2%) were vaccinated with COVID-19 vaccines, with a low incidence of relevant adverse events. More importantly, no new MIS-C or myocarditis occurred after a median of 10 weeks (range 5.3-19.7) post-vaccination.

Keywords: COVID-19; acceptance; multisystem inflammatory syndrome in children (MIS-C); safety; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of enrolled MIS-C patients 12-18 years old.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC). Interim clinical considerations for use of covid-19 vaccines currently approved or authorized in the United States. Accessed May 16, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-co....
    1. Comité Asesor de Vacunas. Síndrome inflamatorio multisistémico pediátrico (SIMP) y vacunas de la COVID. Accessed May 16, 2022. https://vacunasaep.org/profesionales/noticias/vacunas-covid19-y-sindrome...
    1. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. Accessed December 20, 2021. https://www.who.int/publications/i/item/multisystem-inflammatory-syndrom...
    1. Tagarro A, Cobos-Carrascosa E, Villaverde S, et al. EPICO-AEP Working Group. Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish children. Eur J Pediatr 2022; 181:1105–15. - PMC - PubMed
    1. Hause A, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12–17 years—United States, December 14, 2020–July 16, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1053–8. - PMC - PubMed

Substances

Supplementary concepts